Skip to content

Study · Randomized controlled trial · n = 20 · 2011

2 results

Intranasal oxytocin reduces psychotic symptoms and improves Theory of Mind and social perception in schizophrenia.

Pedersen CA, Gibson CM, Rau SW, Salimi K, Smedley KL, Casey RL, Leserman J, Jarskog LF, Penn DL

Schizophrenia research15 Aug 2011Cited by 231 (Europe PMC)

PMID21840177 (opens in a new tab)DOI10.1016/j.schres.2011.07.027 (opens in a new tab)PepBankPUB-21840177
Publisher pagePubMedAsk about this study
Jump to 2 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study2

2 results from studies that gave the peptide. 2 results from people.

  1. 01HumanRandomized controlled trialEfficacy outcome

    In patients with schizophrenia, PANSS scores declined significantly with twice daily intranasal oxytocin for 14 days, but not with placebo.

    In plain wordsIn people with schizophrenia, symptom scores fell with nasal oxytocin for 14 days but not with placebo.

    Peptide
    Oxytocin
    Outcome
    DecreasePANSS psychotic symptom scores
    Study

    n = 20

    Comparator
    Placebo
    Outcome group
    Anxiety and mood · Mental health and mood
    Studied dose
    Dose not stated · intranasal · 14 days, twice dailyAs given in this study (human).

    Source sentences

    Summary
    PANSS scores declined significantly and several social cognition measures improved significantly or nearly significantly in oxytocin (N=11) but not placebo (N=9) recipients.
    1 context sentence
    Summary · context
    We conducted a randomized, placebo-controlled trial testing the effects of twice daily intranasal oxytocin treatment for 14 days on psychotic symptoms and social cognition in patients with schizophrenia.
  2. 02HumanRandomized controlled trialEfficacy outcome

    In patients with schizophrenia, several social cognition measures improved significantly or nearly significantly with intranasal oxytocin, but not with placebo.

    In plain wordsIn people with schizophrenia, several social thinking measures improved or nearly improved with nasal oxytocin but not with placebo.

    Peptide
    Oxytocin
    Outcome
    IncreaseSocial cognition measures
    Study

    n = 20

    Comparator
    Placebo
    Outcome group
    Cognition and memory · Mental health and mood
    Studied dose
    Dose not stated · intranasal · 14 days, twice dailyAs given in this study (human).

    Source sentences

    Summary
    PANSS scores declined significantly and several social cognition measures improved significantly or nearly significantly in oxytocin (N=11) but not placebo (N=9) recipients.
    1 context sentence
    Summary · context
    We conducted a randomized, placebo-controlled trial testing the effects of twice daily intranasal oxytocin treatment for 14 days on psychotic symptoms and social cognition in patients with schizophrenia.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    11 Oct 2026, 01:30 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 02:49 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.